ESTRO 36 Abstract Book

S393 ESTRO 36 2017 _______________________________________________________________________________________________

major bleeding during the course of anticoagulation in cancer patients with or without RT. Results As of May 2015, 9284 patients with active cancer and VTE were enrolled in RIETE: 4605 with pulmonary embolism (PE) and 4679 with deep vein thrombosis (DVT). In all, 1202 (13%) were receiving RT. During the course of anticoagulant therapy (mean: 181 days), 210 patients presented with PE recurrences (53 fatal), 226 with DVT recurrences and 443 with major bleeding (60 in the brain, 118 fatal). Patients receiving RT had a higher rate of PE recurrences (risk ratio [RR]: 1.56; 95%CI: 1.08-2.21) and a similar rate of DVT recurrences (RR: 0.80; 95%CI: 0.50- 1.22) or major bleeding (RR: 1.18; 95%CI: 0.90-1.55) than those not receiving RT. Moreover, patients on RT had a higher rate of cerebral bleeding (RR: 2.05; 95%CI: 1.07- 3.71). Multivariable analysis confirmed that patients receiving radiotherapy were at an increased risk for cerebral bleeding (hazard ratio: 2.71; 95%CI: 1.13-6.48). Conclusion During the course of anticoagulant therapy, cancer patients with VTE receiving RT had a higher rate of PE recurrence and a higher rate of cerebral bleeding than those not receiving RT. PO-0754 ISIORT pooled analysis 2016: characteristics of intraoperative radiotherapy in 11,025 patients M. Krengli 1 , F. Calvo 2 , F. Sedlmayer 3 , C. Schumacher 4 , F. Cazzaniga 5 , M. Alessandro 6 , A. De Paoli 7 , E. Russi 8 , M. Kruszyna 9 , R. Corvò 10 , F. Wenz 11 , R. Mazzarotto 12 , F. Fusconi 13 , A. Ciabattoni 14 , R. Weytjens 15 , G. Ivaldi 16 , A. Baldissera 17 , C. Pisani 1 , V. Morillo 18 , M. Osti 19 , N. Bese 20 , G. Catalano 21 , A. Stefanelli 22 , C. Iotti 23 , L. Tomio 24 1 University of Piemonte Orientale, Radiotherapy, Novara, Italy 2 Gregorio Maranon, Radiotherapy, Madrid, Spain 3 Paracelsus Medical University, Radiotherapy, Salzburg, Austria 4 St. Elisabeth Hospital, Radiotherapy, Cologne, Germany 5 ASST Papa Giovanni XXIII, Radiotherapy, Bergamo, Italy 6 Ospedale USL1, Radiotherapy, Città di Castello, Italy 7 CRO, Radiotherapy, Aviano, Italy 8 Azienda Ospedaliera S. Croce e Carle, Radiotherapy, Cuneo, Italy 9 Hospital, Radiotherapy, Poznan, Poland 10 Ospedale San Martino, Radiotherapy, Genova, Italy 11 University Hospital, Radiotherapy, Mannheim, Germany 12 University Hospital, Radiotherapy, Verona, Italy 13 Hospital, Radiotherapy, Foligno, Italy 14 San Filippo Neri Hospital, Radiotherapy, Roma, Italy 15 GasthuisZusters Antwerpen -GZA, Radiotherapy, Wilrijk, Belgium 16 Fondazione Maugeri, Radiotherapy, Pavia, Italy 17 Bellaria Hospital, Radiotherapy, Bologna, Italy 18 Hospital General Universitario de Castellón, Radiotherapy, Castellon, Spain 19 Sant'Andrea Hospital, Radiotherapy, Roma, Italy 20 Acibadem Maslak Hospital, Radiotherapy, Istanbul, Turkey 21 Multimedica Hospital, Radiotherapy, Sesto San Giovanni- Castellanza, Italy 22 Sant'Anna Hospital, Radiotherapy, Ferrara, Italy 23 Azienda Ospedaliera di Reggio Emilia, Radiotherapy, Reggio Emilia, Italy 24 Santa Chiara Hospital, Radiotherapy, Trento, Italy Purpose or Objective Data from centres active in intraoperative radiotherapy (IORT) were collected within the International Society of Intraoperative Radiotherapy (ISIORT) program. The purpose of the present analysis was to analyse and report the main clinical and technical variables of IORT performed by the participating centres. Material and Methods

In 2007, the ISIORT-Europe centres were invited to record demographic, clinical and technical data relating to their IORT procedures in a joint online database. Results The numbers of centres increased from 3 centres in 2007 to 42 centres and 11,025 IORT procedures have been recorded until October, 2016. 96% of treatment was performed with electrons, while 448 treatments were performed with x-rays. Median age of patients was 56.2 years (range: 5 months – 89 years). Gender was female in 81.2% of cases and male in 18.8%. Treatments were curative in 10,482 cases (98.2%) and 2,545 (23.8%) cases were included in study protocols. The most frequent tumour was breast cancer with 8,425 cases (76.4%) followed by rectal cancer with 913 cases (8.3%), soft tissue and bone sarcomas with 348 cases (3.2%), prostate cancer with 165 cases (1.5%), gastric cancer with 120 cases (1.1%) and pancreatic cancer with 117 cases (1.1%). 22% of patients were included in study protocols. Focusing on breast cancer: 96.5% of cases were ductal carcinoma, 99.5% treatments had curative intense and 113 cases were re-treating with IORT. Conclusion Treatment chronology shows how IORT number of recorded cases increased according with the interest in this ISIORT project. This survey gives an overview of worldwide use of IORT including patient selection criteria and treatment modalities and could represent a basis to design future clinical trials. PO-0755 Implementation of structural patient reported outcome registration in clinical practice I. Nijsten - van Riesen 1 , L. Boersma 2 , M. Brouns 1 , A. Dekker 3 , K. Smits 4 1 MAASTRO Clinic, Projectmanager Datacentre Maastro Clinic DCM, Maastricht, The Netherlands 2 MAASTRO Clinic, Director of Patient Care, Maastricht, The Netherlands 3 MAASTRO Clinic, Manager Research and Education, Maastricht, The Netherlands 4 MAASTRO Clinic, Manager of Datacentre Maastro Clinic DCM, Maastricht, The Netherlands Purpose or Objective Over the last years there has been an increasing focus on registration and national audits of quality indicators, with the assumption that insights into the quality of a certain treatment will increase outcomes. Within our radiotherapy (RT) institute we have set-up a structural outcome registration, where we first focussed on registration of toxicity, both reported by the doctor and by the patient. The reported toxicity was stored in a data warehouse including dashboards to evaluate toxicity on a population level, and to identify potential targets for improvements in the quality of care. The current study was done to investigate how we can directly improve individual patient care by re-directing the patient- reported outcome measures (PROMs) to the responsible radiation oncologist (RO). Material and Methods